Skip to content

Clinical Study on the Treatment of Metabolic Dysfunction-associated Steatotic Liver disease with Pingwei Anshen Decoction Based on the Theory of Brain and Liver Treatment

Clinical Study on the Treatment of Metabolic Dysfunction-associated Steatotic Liver disease with Pingwei Anshen Decoction Based on the Theory of Brain and Liver Treatment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000397
Enrollment
Unknown
Registered
2025-02-24
Start date
2024-09-25
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Dysfunction-associated Steatotic Liver disease

Interventions

Control group:Traditional chinese medicine simulant
Treatment group:Pingwei Anshen Decoction

Sponsors

Dongzhimen Hospital Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-70 years old male or female; (2) In line with MASLD Western diagnostic criteria and liver stagnation and spleen deficiency phlegm stasis interjunction TCM syndrome diagnosis criteria; (3) Voluntarily participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) intolerance of any Chinese medicine ingredient; (2) pregnant and lactating women; (3) eating difficulties complicated with tumors heart and kidney failure and other serious organ diseases; (4) Use of weight loss drugs such as orlistat within 1 month before

Design outcomes

Primary

MeasureTime frame
TCM syndrome integral;CAP;

Secondary

MeasureTime frame
ALP;ALT;FPG;HOMA-IR;VAS;HDL-C;C-P;Ghrelin;Leptin;FINS;BMI;TG;AST;TC;LDL-C;GGT;

Countries

China

Contacts

Public ContactDu Hong Bo

Dongzhimen Hospital Beijing University of Chinese Medicine

duhongbotcm@126.com+86 138 1051 6683

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026